https://www.selleckchem.com/products/CAL-101.html
Surgery is frequently required in persons with haemophilia A (PwHA). Emicizumab, a bispecific, humanized monoclonal antibody, bridges activated factor (F) IX and FX. Management of patients undergoing surgery while receiving emicizumab is of clinical interest due to paucity of data. Review real-world experience of PwHA with/without FVIII inhibitors who required surgery while receiving emicizumab prophylaxis. Data regarding peri-operative management, including type of surgery, haemostatic agent use and bleeding complications, were collect
Like
Comment
Share
